Journal of Affective Disorders Reports
June 8, 2026
Marzieh Jalalian-Javadpour, Batool Ghorbani Yekta, Niloufar Reyhani et al.
Psilocybin is a chemical compound found in certain types of hallucinogenic mushrooms, known as magic mushrooms. Evidence has shown potential therapeutic effects of psilocybin on different neuropsychiatric disorders such as major depressive disorder (MDD), posttraumatic stress disorder (PTSD), anxiety disorders, and obsessive-compulsive disorder (OCD). Although the efficacy of psilocybin in...
Scientific Reports
August 23, 2025
Kalin Manooki, Mahdieh Gholami, Maryam Eslami et al.
3 citations
Schizophrenia is a severe chronic neuropsychiatric disorder with a wide-range of cognitive and mental deficits and different categories of symptoms including positive, negative, and cognitive symptoms. In rodents, sub-chronic ketamine administration is a common method to induce a schizophrenia-like state. Olanzapine, an atypical antipsychotic medication, is used for the treatment and management...
Behavioural Pharmacology
April 1, 2025
Eghbal Jasemi, Ali Razmi, Salar Vaseghi et al.
5 citations
Maternal separation as an early life stress can lead to long-lasting deleterious effects on cognitive and behavioral functions, and the mood state. On the other hand, Psilocybe cubensis (as one of the most well-known magic mushrooms) may be beneficial in the improvement or the treatment of neuropsychiatric disorders. In the present study, we aimed to investigate the effect of P. cubensis...
Naunyn-Schmiedeberg's archives of pharmacology
February 20, 2025
Atefeh Motamedi-Manesh, Mahdieh Farzin Asanjan, Hamed Fallah et al.
6 citations
Schizophrenia is a severe neuropsychiatric disorder ranking among the top ten global disability causes. In rodents, sub-chronic or chronic ketamine treatment is used for the induction of schizophrenia. Ketamine affects the function of brain-derived neurotrophic factor (BDNF), the most important neurotrophin involved in the pathophysiology of different neuropsychiatric disorders. The present...
Journal of Psychoactive Drugs
November 13, 2024
Reza Ghaffarzadegan, Mokhtar Karimi, Behnaz Hedayatjoo et al.
6 citations
Psilocybin-containing mushrooms, commonly known as magic mushrooms, drastically affect mental processing, cognitive functioning, and the mood state. In the present study, we investigated the effect of the Psilocybe cubensis extract on spatial memory and the brain-derived neurotrophic factor (BDNF) in rats exposed to chronic unpredictable mild stress (CUMS). The duration of CUMS was 4 weeks....
Journal of Psychiatric Research
October 1, 2024
Mohammad-Ali Samizadeh, Seyedeh-Tabassom Abdollahi-Keyvani, Hamed Fallah et al.
21 citations
Schizophrenia is a complex neuropsychiatric disorder with positive, negative, and cognitive symptoms. In rats, sub-chronic administration of ketamine is used for the induction of schizophrenia model. Increased locomotor activity is one of the most important features of psychotic-like symptoms in rodents. On the other hand, risperidone is a potent antipsychotic medication that is approved for...
Behavioral Neuroscience
January 18, 2024
Zahra Ghofrani-Jahromi, Sarah Nouri-Darehno, Mehrsa Rahimi-Danesh et al.
22 citations
Psilocybe cubensis is a species of psilocybin mushroom (magic mushroom) of moderate potency whose principal active compounds are psilocybin and psilocin. Recent studies have shown the significant procognitive and mood-enhancer effects of Psilocybe cubensis. However, evidence is so limited, especially in preclinical studies. We aimed to investigate the effect of Psilocybe cubensis extract on...